TCGA-DK-AA75-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 11.1695138
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.470
- E2F_TARGETS+0.240
- KRAS_SIGNALING_DN+0.230
- MYC_TARGETS_V1+0.220
- SPERMATOGENESIS+0.210
- DNA_REPAIR+0.190
- OXIDATIVE_PHOSPHORYLATION+0.190
- PANCREAS_BETA_CELLS+0.100
- G2M_CHECKPOINT+0.060
- BILE_ACID_METABOLISM+0.030
Top 10 suppressed
- TGF_BETA_SIGNALING-0.560
- INTERFERON_GAMMA_RESPONSE-0.530
- INFLAMMATORY_RESPONSE-0.520
- INTERFERON_ALPHA_RESPONSE-0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- IL6_JAK_STAT3_SIGNALING-0.510
- PROTEIN_SECRETION-0.480
- TNFA_SIGNALING_VIA_NFKB-0.480
- UV_RESPONSE_DN-0.480
- ALLOGRAFT_REJECTION-0.470
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-P3-A6T6-01A-11R-A34R-07 | — | — | 0.949 |
| 2 | SRR8526719 | — | cohortMD1 | 0.938 |
| 3 | TCGA-E5-A4U1-01A-11R-A31N-07 | — | — | 0.935 |
| 4 | TCGA-CN-A63U-01A-11R-A30B-07 | — | — | 0.931 |
| 5 | TCGA-OL-A5RZ-01A-11R-A28M-07 | — | C | 0.921 |
| 6 | TCGA-77-A5G7-01B-11R-A27Q-07 | — | cohortSQ1 | 0.916 |
| 7 | R16 | — | — | 0.915 |
| 8 | TCGA-E9-A54Y-01A-11R-A466-07 | — | B | 0.913 |
| 9 | TCGA-AN-A0AR-01A-11R-A00Z-07 | — | E | 0.911 |
| 10 | TCGA-QK-A8Z7-01A-11R-A39I-07 | — | — | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.060 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |